Go to the list of all blogs
Joma Foster's Avatar
published in Blogs
Aug 03, 2026
CF Industries Holdings (CF): Can It Reach the Street-High $150 Price Target?

CF Industries Holdings (CF): Can It Reach the Street-High $150 Price Target?

Key Takeaways

  • CF Industries Holdings, Inc. (NYSE: CF) currently trades around $125, and the $150 price target represents the Street-high analyst forecast — about 20% above recent levels and roughly 9% above the stock's all-time high near $138.
  • The strongest bullish argument centers on tight global nitrogen supply, elevated fertilizer prices driven by geopolitical instability, and CF's structural cost advantage from low-cost U.S. natural gas feedstock.
  • The biggest obstacles include a consensus analyst rating of Hold, recent price-target cuts from several major firms, and the inherently cyclical nature of nitrogen fertilizer earnings — with fiscal 2027 EPS expected to decline by roughly 28%.
  • Key technical levels include the all-time high near $138 as major resistance, with psychological support around $100 and the 52-week low near $75.
  • The central takeaway: $150 is achievable under a sustained nitrogen upcycle, but the stock's powerful rally has already priced in considerable optimism, making further gains heavily dependent on continued supply disruptions and crop price strength.

Why the $150 Target Stands Out

Among the 19 to 21 analysts covering CF Industries Holdings, Inc. (CF), the $150 price target stands out as the most bullish call on Wall Street. Wells Fargo analyst Michael Sison reiterated an Overweight rating with this target in May 2026, and firms including Barclays and Freedom Capital Markets have set targets at $145 and $147 respectively — clustering just below the $150 threshold. For investors scanning the analyst landscape, $150 has become shorthand for the bull case, especially after the stock surged roughly 55% year-to-date in 2026 and touched an all-time high of approximately $138 in March.

A Quick Look at CF Industries

CF Industries is the world's largest ammonia producer and a leading global manufacturer of nitrogen-based products. Headquartered in Northbrook, Illinois, the company operates nine world-scale manufacturing complexes across the United States, Canada, and the United Kingdom, producing approximately 10 million tons of ammonia annually. Its product portfolio spans anhydrous ammonia, granular urea, urea ammonium nitrate (UAN), ammonium nitrate, and diesel exhaust fluid. Because CF manufactures nitrogen using low-cost U.S. natural gas as its primary feedstock, it ranks among the lowest-cost nitrogen producers globally — a structural advantage that underpins its profitability during commodity upcycles.

Factors Supporting a Move Higher

Several converging factors support the possibility of CF reaching $150. First, global nitrogen markets remain tight. Ongoing geopolitical tensions — particularly in the Middle East — have disrupted fertilizer supply chains and pushed nitrogen prices higher. Higher crop prices have simultaneously strengthened farmer purchasing power, supporting demand for nitrogen fertilizer during key planting seasons.

Second, CF's financial performance has been exceptional. First-quarter 2026 results showed net sales up 20% and earnings per share (EPS) nearly doubling year-over-year. The full-year 2026 EPS consensus sits at roughly $15.86, approximately 69% above the prior year. The company also announced a 20% dividend increase, signaling management confidence in cash generation.

Third, CF's valuation remains relatively modest. Even after the rally, the stock trades at a trailing price-to-earnings (P/E) ratio of roughly 11x — well below the broader U.S. chemicals industry average of approximately 24x. If nitrogen pricing remains elevated and the market assigns a higher multiple, a move toward $150 becomes mathematically plausible. A discounted cash flow analysis using free cash flow projections has suggested a fair value above $150 in certain scenarios. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Risks That Could Cap Gains

Despite the bullish narrative, significant headwinds could keep $150 out of reach. The most immediate concern is that much of the good news may already be priced in. With the stock up more than 55% year-to-date, the average analyst price target sits near $125 — essentially flat from current levels. Several major firms, including Morgan Stanley, Goldman Sachs, and UBS, trimmed their price targets during mid-2026, and the overall consensus rating across 19-plus analysts remains a cautious Hold.

The cyclical nature of nitrogen fertilizer earnings represents another major risk. While fiscal 2026 EPS is projected at $15.86, consensus estimates for fiscal 2027 point to a sharp decline toward approximately $11.36 — a drop of about 28%. Markets tend to price stocks on forward expectations, and if investors begin discounting a 2027 earnings contraction, the stock could struggle to sustain upward momentum.

An ongoing Department of Justice (DOJ) pricing probe into the fertilizer industry adds regulatory uncertainty. Additionally, any easing of geopolitical tensions or a meaningful decline in natural gas prices in competing regions like Europe or the Middle East could narrow CF's cost advantage and soften nitrogen prices.

Analyst Opinions Remain Mixed

The analyst community is notably split. Wells Fargo and Barclays maintain bullish stances, with targets at $150 and $145 respectively. Freedom Capital Markets upgraded CF to Buy with a $147 target in May 2026. Yet BofA Securities, Mizuho, and Rothschild & Co Redburn sit on the opposite side, with ratings of Underperform or Sell and price targets ranging from $72 to $106. This wide dispersion — from $72 on the low end to $150 on the high end — reflects genuine uncertainty about whether current nitrogen pricing strength can persist beyond the near term. The average target of roughly $125 suggests that, as a group, analysts see the stock as fairly valued at current levels.

Important Technical Levels to Watch

From a technical perspective, CF's all-time high near $138 serves as the most important resistance level. A decisive break above that level — ideally on above-average volume — would likely be required before $150 becomes a realistic near-term objective. On the downside, the $100 level has acted as an important psychological and structural support zone, reinforced by the stock's 52-week low near $75. The stock's rapid ascent from the high $70s to the mid-$130s means the intermediate support zones are less well-defined, which could contribute to heightened volatility during any pullback. From what I see, these levels remain key reference points for any position sizing decisions.

My Take on the Outlook

The question of whether CF Industries can reach $150 hinges on the durability of the current nitrogen upcycle. The bull case — tight global supply, favorable agricultural economics, low-cost U.S. natural gas, and a still-modest P/E multiple — provides a credible pathway to the Street-high target. However, the bear case is equally substantial: a consensus Hold rating, recent analyst downgrades and target cuts, projected earnings contraction in 2027, and a stock that has already absorbed enormous gains. For $150 to materialize, nitrogen prices would likely need to remain elevated well into 2027, geopolitical supply disruptions would need to persist, and the market would need to assign CF a higher earnings multiple than it currently does. Investors should watch nitrogen price trends, crop futures, geopolitical developments, and the DOJ probe as key indicators of whether the rally has further to run.

AI Tools in My Research Process

One resource I turn to when sorting through volatile names and mixed signals is Tickeron’s AI Daily Buy/Sell Signals. The platform applies artificial intelligence to scan thousands of stocks and ETFs, delivering Buy, Sell, or Hold signals based on technical behavior and evolving market conditions. It helps me quickly cross-check ideas without manually reviewing every chart and report, which keeps the analysis process more efficient when evaluating opportunities like CF.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: CF

CF in downward trend: price may decline as a result of having broken its higher Bollinger Band on July 22, 2026

CF broke above its upper Bollinger Band on July 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 47 similar instances where the stock broke above the upper band. In of the 47 cases the stock fell afterwards. This puts the odds of success at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for CF moved out of overbought territory on July 24, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 39 similar instances where the indicator moved out of overbought territory. In of the 39 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on August 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CF as a result. In of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for CF turned negative on August 03, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 53 similar instances when the indicator turned negative. In of the 53 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CF declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 58 cases where CF's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

CF moved above its 50-day moving average on August 10, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for CF crossed bullishly above the 50-day moving average on July 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CF advanced for three days, in of 346 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 282 cases where CF Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock slightly better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CF's P/B Ratio (3.160) is slightly higher than the industry average of (1.314). P/E Ratio (8.903) is within average values for comparable stocks, (47.267). CF's Projected Growth (PEG Ratio) (2.331) is slightly higher than the industry average of (1.470). Dividend Yield (0.017) settles around the average of (0.042) among similar stocks. P/S Ratio (2.425) is also within normal values, averaging (1.414).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

Notable companies

The most notable companies in this group are CF Industries Holding (NYSE:CF), Mosaic Company (The) (NYSE:MOS).

Industry description

The agricultural chemicals sector includes companies that produce chemical products for the agricultural industry applications like crop protection, animal health, biotechnology and pharmaceutical-related products. Some of the largest agricultural chemicals producers include Nutrien Ltd., Corteva Inc., and FMC Corporation.

Market Cap

The average market capitalization across the Chemicals: Agricultural Industry is 9.37B. The market cap for tickers in the group ranges from 14.68K to 50.39B. CTVA holds the highest valuation in this group at 50.39B. The lowest valued company is CGSI at 14.68K.

High and low price notable news

The average weekly price growth across all stocks in the Chemicals: Agricultural Industry was -1%. For the same Industry, the average monthly price growth was -3%, and the average quarterly price growth was -13%. IPI experienced the highest price growth at 8%, while AVD experienced the biggest fall at -15%.

Volume

The average weekly volume growth across all stocks in the Chemicals: Agricultural Industry was -20%. For the same stocks of the Industry, the average monthly volume growth was 26% and the average quarterly volume growth was -14%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 37
P/E Growth Rating: 64
Price Growth Rating: 58
SMR Rating: 82
Profit Risk Rating: 82
Seasonality Score: -15 (-100 ... +100)
View a ticker or compare two or three
CF
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a manufacturer of nitrogen fertilizer products

Industry ChemicalsAgricultural

Profile
Details
Industry
Chemicals Agricultural
Address
2375 Waterview Drive
Phone
+1 847 405-2400
Employees
2700
Web
https://www.cfindustries.com
Interact to see
Advertisement
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.
Gogo shares continue to trade near 52-week lows around $4, weighed down by competitive threats from Starlink and slower-than-anticipated AVANCE system upgrades. William Blair downgraded the stock to Market Perform in December 2025, citing leverage concerns and intensifying rivalry in in-flight connectivity.
Quantum Computing Inc. completed a $110 million acquisition of Luminar Semiconductor on February 2, significantly strengthening its photonics and manufacturing capabilities. Shares have traded with elevated volatility, peaking near $12.70 in mid-January before retreating to the $9 range amid heavy volume.
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.